- Home
- SERA vs ADAG Comparison
SERA vs ADAG Comparison
Compare SERA & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERA
- ADAG
- Stock Information
- Founded
- SERA 2008
- ADAG 2011
- Country
- SERA United States
- ADAG China
- Employees
- SERA N/A
- ADAG N/A
- Industry
- SERA Precision Instruments
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- SERA Health Care
- ADAG Health Care
- Exchange
- SERA Nasdaq
- ADAG Nasdaq
- Market Cap
- SERA 90.6M
- ADAG 84.4M
- IPO Year
- SERA 2021
- ADAG 2021
- Fundamental
- Price
- SERA $2.76
- ADAG $1.61
- Analyst Decision
- SERA
- ADAG Strong Buy
- Analyst Count
- SERA 0
- ADAG 3
- Target Price
- SERA N/A
- ADAG $7.67
- AVG Volume (30 Days)
- SERA 41.8K
- ADAG 53.4K
- Earning Date
- SERA 11-13-2025
- ADAG 08-12-2025
- Dividend Yield
- SERA N/A
- ADAG N/A
- EPS Growth
- SERA N/A
- ADAG N/A
- EPS
- SERA N/A
- ADAG N/A
- Revenue
- SERA $108,000.00
- ADAG $103,204.00
- Revenue This Year
- SERA $217.92
- ADAG $7,411.34
- Revenue Next Year
- SERA $479.25
- ADAG $28.29
- P/E Ratio
- SERA N/A
- ADAG N/A
- Revenue Growth
- SERA 0.94
- ADAG N/A
- 52 Week Low
- SERA $1.37
- ADAG $1.33
- 52 Week High
- SERA $9.13
- ADAG $3.16
- Technical
- Relative Strength Index (RSI)
- SERA 36.93
- ADAG 38.71
- Support Level
- SERA $3.02
- ADAG $1.47
- Resistance Level
- SERA $3.21
- ADAG $1.93
- Average True Range (ATR)
- SERA 0.25
- ADAG 0.14
- MACD
- SERA -0.08
- ADAG -0.02
- Stochastic Oscillator
- SERA 4.53
- ADAG 29.17
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.